Pir2/Rnf144b is a potential endometrial cancer biomarker that promotes cell proliferation.
Name:
s41419-018-0521-1.pdf
Size:
1005.Kb
Format:
PDF
Description:
Full text, Open Access article
Affiliation
University of Manchester, Faculty of Medical and Human Sciences, Division of Cancer Sciences, Manchester Cancer Research Centre, Wilmslow Road, Manchester, M20 4QL, UKIssue Date
2018-05-02
Metadata
Show full item recordAbstract
Endometrial cancer is one of the most common gynaecological cancers in developed countries. Its incidence has increased 20% over the last decade and the death rate has increased >100% over the past two decades. Current models for prediction of prognosis and treatment response are suboptimal, and as such biomarkers to support clinical decision-making and contribute to individualised treatment are needed. In this study, we show that the E3-ubiquitin ligase PIR2/RNF144B is a potential targetable biomarker in endometrial cancer. At transcript level, it is expressed both in normal endometrium and tumour samples, but at protein level, it is expressed in tumours only. By using endometrial cancer cell lines, we demonstrated that PIR2/RNF144B is stabilised via phosphorylation downstream of GSK3β and this is necessary for the proliferation of endometrial cancer cells, in the absence of oestrogenic growth stimuli. Here, inactivation of GSK3β activity is associated with loss of PIR2/RNF144B protein and consequent inhibition of cell proliferation. Our results, therefore, substantiate PIR2/RNF144B as a novel candidate for targeted therapy in endometrial cancer.Citation
Pir2/Rnf144b is a potential endometrial cancer biomarker that promotes cell proliferation. 2018, 9(5): 504 Cell Death DisJournal
Cell Death & DiseaseDOI
10.1038/s41419-018-0521-1PubMed ID
29724995Type
ArticleLanguage
enISSN
2041-4889ae974a485f413a2113503eed53cd6c53
10.1038/s41419-018-0521-1
Scopus Count
Collections
Related articles
- PIR2/Rnf144B regulates epithelial homeostasis by mediating degradation of p21WAF1 and p63.
- Authors: Conforti F, Yang AL, Piro MC, Mellone M, Terrinoni A, Candi E, Tucci P, Thomas GJ, Knight RA, Melino G, Sayan BS
- Issue date: 2013 Oct
- ATX‑LPA axis facilitates estrogen‑induced endometrial cancer cell proliferation via MAPK/ERK signaling pathway.
- Authors: Zhang G, Cheng Y, Zhang Q, Li X, Zhou J, Wang J, Wei L
- Issue date: 2018 Mar
- Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer.
- Authors: Huang KT, Pavlides SC, Lecanda J, Blank SV, Mittal KR, Gold LI
- Issue date: 2012
- Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer.
- Authors: Yin Y, Kizer NT, Thaker PH, Chiappinelli KB, Trinkaus KM, Goodfellow PJ, Ma L
- Issue date: 2013 Aug 12
- Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3β/β-catenin signaling.
- Authors: Lin Y, Chen X, Lin L, Xu B, Zhu X, Lin X
- Issue date: 2024 May 2